It seems the virus is still showing up in the patient’s blood, which clinicians thought couldn’t happen when the infection is controlled with medication. University of Pittsburgh School of Medicine scientists report today that they’ve solved the mystery—and the answer has clinical implications.
In a study published in the Journal of Clinical Investigation, Pitt infectious disease researchers show that the issue isn’t nonadherence to medication or resistance to the drugs. Instead, the patients are victims of what the scientists have dubbed “repliclones”—large clones of HIV-infected cells that produce infectious virus particles.
“We found that repliclones can grow large enough and produce enough virus to make it appear that antiretroviral therapy isn’t working completely even when it is,” said senior author John Mellors, who holds the Endowed Chair for Global Elimination of HIV and AIDS, and is chief of the Division of Infectious Diseases at Pitt and UPMC.
HIV replicates by taking over a cell’s machinery and using it to produce more virus, which can then go on to infect other cells. Antiretroviral therapy, which is taken daily, prevents the virus from infecting new cells. So, even though HIV can’t yet be cured, it can be controlled to the point that it isn’t detectable in blood tests.
Elias Halvas, a research assistant professor in Pitt’s Division of Infectious Diseases, and Mellors led a multidisciplinary team of U.S.-based HIV scientists in investigating the medical records and blood from eight patients with non-suppressible HIV viremia—meaning, detectable virus in the blood—despite adherence to antiretroviral medications. Repeated samples of each patient’s blood revealed identical viral genetic sequences that did not change over time.
“This indicates that, in the individual patients, the virus in their blood was coming from identical cellular factories,” said Halvas.
In short, rather than the virus infecting new cells, already infected HIV-producing cells are growing into large clones that make and release virus. Current medications for HIV infection block the virus from infecting new cells but don’t affect virus production from cells or clones of cells that are already infected.
“Even though we don’t have evidence that the virus produced by these repliclones is then infecting new cells—which would be detrimental to the patient’s immune system—they could cause other problems, such as chronic inflammation,” said Mellors, who is also Distinguished Professor of Medicine at Pitt. “If the patient were to stop drug therapy, the virus could have a head-start on rebounding. And repliclones are a key barrier to developing a true cure for HIV.”
The immediate implication of their discovery, Mellors said, involves informing clinicians and patients that HIV viremia can be caused by repliclones. This can help clinicians in developing disease management plans that may allow continuation of current antiretroviral regimen, knowing that switching the treatment regimen may not suppress the viremia. Instead, the patient can be monitored over time to exclude for the development of drug resistance—which would dictate a change in medication—in patients with repliclones.
For the long-term, scientists must figure out how repliclones escape the immune system’s attention and how they can be efficiently killed to cure the infection. While more research is needed, Mellors and his team speculate that smaller, less easily detected repliclones may be present throughout the body and be responsible for the rapid rebound of HIV in patients who stop their therapy. An added complexity is that not all the cells of a repliclone may be making the virus at the same time and thus could remain hidden from the immune system as a latent or invisible reservoir of HIV.
“Many scientists around the globe are working hard to expose the HIV reservoir and destroy it,” said Halvas.
This research was funded by National Cancer Institute; the Howard Hughes Medical Institute; the Bill & Melinda Gates Foundation; the National Institute for Allergy and Infectious Diseases; the Office of AIDS Research; the American Cancer Society and the University of Rochester HIV/AIDS Clinical Trials Unit.
